CN112204032A - 杂环衍生物及其用途 - Google Patents

杂环衍生物及其用途 Download PDF

Info

Publication number
CN112204032A
CN112204032A CN201980035540.4A CN201980035540A CN112204032A CN 112204032 A CN112204032 A CN 112204032A CN 201980035540 A CN201980035540 A CN 201980035540A CN 112204032 A CN112204032 A CN 112204032A
Authority
CN
China
Prior art keywords
pyrazin
pyrido
bromo
imidazo
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980035540.4A
Other languages
English (en)
Chinese (zh)
Inventor
高广硕
李顺玉
权永镇
尹智勋
赵南哲
李智恩
金贞淑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C&c Institute Of New Drugs
Original Assignee
C&c Institute Of New Drugs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&c Institute Of New Drugs filed Critical C&c Institute Of New Drugs
Publication of CN112204032A publication Critical patent/CN112204032A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201980035540.4A 2018-05-31 2019-05-31 杂环衍生物及其用途 Pending CN112204032A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180062254 2018-05-31
KR10-2018-0062254 2018-05-31
PCT/KR2019/006553 WO2019231270A1 (en) 2018-05-31 2019-05-31 Heterocyclic derivatives and use thereof

Publications (1)

Publication Number Publication Date
CN112204032A true CN112204032A (zh) 2021-01-08

Family

ID=68698381

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980035540.4A Pending CN112204032A (zh) 2018-05-31 2019-05-31 杂环衍生物及其用途

Country Status (12)

Country Link
US (1) US20210198259A1 (https=)
EP (1) EP3807282A4 (https=)
JP (1) JP2021525738A (https=)
KR (1) KR102344295B1 (https=)
CN (1) CN112204032A (https=)
AU (1) AU2019279421A1 (https=)
BR (1) BR112020023946A2 (https=)
CA (1) CA3098825A1 (https=)
MX (1) MX2020011955A (https=)
SG (1) SG11202010985TA (https=)
TW (1) TW202021969A (https=)
WO (1) WO2019231270A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929634A (zh) * 2021-11-22 2022-01-14 山西永津集团有限公司 一种2,3-二溴喹喔啉的合成方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
IL298760A (en) 2020-06-05 2023-02-01 Kinnate Biopharma Inc Fibroblast growth factor receptor kinase inhibitors
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1205519A (en) * 1967-09-27 1970-09-16 Siegfried Ag Novel 1,2-dihydro-benztriazine derivatives and process for preparing the same
US20040192698A1 (en) * 2003-03-27 2004-09-30 Pfizer Inc. Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
WO2010030785A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011112731A2 (en) * 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012012264A1 (en) * 2010-07-19 2012-01-26 Alcon Research, Ltd. Methods and compositions for the treatment of allergy
WO2013048214A2 (en) * 2011-09-30 2013-04-04 C&C Research Laboratories Novel heterocyclic derivatives and their uses
WO2014152029A2 (en) * 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
WO2017085053A1 (en) * 2015-11-16 2017-05-26 Fundación Para La Investigación Médica Aplicada Novel compounds as inhibitors of dna methyltransferases
WO2018022865A1 (en) * 2016-07-28 2018-02-01 Promega Corporation Coelenterazine analogues

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1205519A (en) * 1967-09-27 1970-09-16 Siegfried Ag Novel 1,2-dihydro-benztriazine derivatives and process for preparing the same
US20040192698A1 (en) * 2003-03-27 2004-09-30 Pfizer Inc. Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
WO2010030785A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011112731A2 (en) * 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012012264A1 (en) * 2010-07-19 2012-01-26 Alcon Research, Ltd. Methods and compositions for the treatment of allergy
WO2013048214A2 (en) * 2011-09-30 2013-04-04 C&C Research Laboratories Novel heterocyclic derivatives and their uses
WO2014152029A2 (en) * 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
WO2017085053A1 (en) * 2015-11-16 2017-05-26 Fundación Para La Investigación Médica Aplicada Novel compounds as inhibitors of dna methyltransferases
WO2018022865A1 (en) * 2016-07-28 2018-02-01 Promega Corporation Coelenterazine analogues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURBIEL, JOACHIM C.: "2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists" *
HENEN, MORKOS A.: "[1,2,4]Triazolo[4,3-a]quinoxaline: synthesis, antiviral, and antimicrobial activities" *
VICENTE-GARCIA, ESTHER: "New Heterocyclic Inputs for the Povarov Multicomponent Reaction" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929634A (zh) * 2021-11-22 2022-01-14 山西永津集团有限公司 一种2,3-二溴喹喔啉的合成方法

Also Published As

Publication number Publication date
US20210198259A1 (en) 2021-07-01
TW202021969A (zh) 2020-06-16
BR112020023946A2 (pt) 2021-02-23
EP3807282A1 (en) 2021-04-21
MX2020011955A (es) 2021-01-15
SG11202010985TA (en) 2020-12-30
CA3098825A1 (en) 2019-12-05
WO2019231270A1 (en) 2019-12-05
EP3807282A4 (en) 2022-03-02
JP2021525738A (ja) 2021-09-27
KR20190137013A (ko) 2019-12-10
AU2019279421A1 (en) 2020-12-03
KR102344295B1 (ko) 2021-12-29

Similar Documents

Publication Publication Date Title
EP4271672B1 (en) Carboxy-benzimidazole glp-1r modulating compounds
US11629148B2 (en) Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors
JP6293861B2 (ja) Ｐ２ｘ７モジュレータ
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
TW202016109A (zh) 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
CN112204032A (zh) 杂环衍生物及其用途
AU2015204045A1 (en) Heteroaryl substituted nicotinamide compounds
CN109311896A (zh) 吡唑并嘧啶衍生物作为激酶抑制剂
KR20220063228A (ko) 아졸-융합된 피리다진-3(2h)-온 유도체
US11597728B2 (en) Monoacylglycerol lipase modulators
CN114302886A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN115348961A (zh) 杂环pad4抑制剂
TW202321224A (zh) 新型parp7抑制劑及其應用
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
WO2019031990A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
US20250289820A1 (en) Non-covalent modifiers of akt1 and uses thereof
CN111511742A (zh) 作为PDE1抑制剂的吡唑并[3,4-b]吡啶和咪唑并[1,5-b]哒嗪
HK40034987A (en) Heterocyclic derivatives and use thereof
RU2797323C2 (ru) Модуляторы моноацилглицеринлипазы
JP2025516564A (ja) ＮＦ－κＢ誘導性キナーゼの阻害剤としてのピロリジノン誘導体
HK40119556A (zh) 吲唑化合物
CN117597333A (zh) 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
HK40100302A (zh) 作为激酶抑制剂的吲唑类化合物
HK1209114A1 (en) 3-substituted pyrazoles and use as dlk inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034987

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210108